<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03755128</url>
  </required_header>
  <id_info>
    <org_study_id>MOM-M281-103</org_study_id>
    <nct_id>NCT03755128</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn</brief_title>
  <official_title>A Multicenter, Prospective Observational Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Momenta Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Momenta Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to characterize the current standard of care, clinical
      course, and outcomes of pregnant women and their offspring at high risk for early onset
      severe hemolytic disease of the fetus and newborn (EOS-HDFN).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The outcomes of interest will be assessed from the information collected on the standard of
      care treatment for EOS-HDFN in pregnant women and their offspring from current pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Live Birth at or After Gestational Age (GA) Week 32 Without Intrauterine Transfusion (IUT)</measure>
    <time_frame>GA Week 32 through GA Week 37</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Live Birth</measure>
    <time_frame>Up to approximately GA Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants at GA Week 24 Without an IUT</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GA at First IUT</measure>
    <time_frame>Up to approximately GA Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of IUTs Required</measure>
    <time_frame>Up to approximately GA Week 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Fetal Hydrops</measure>
    <time_frame>Post-Birth through Age 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Neonates Requiring Phototherapy</measure>
    <time_frame>Post-Birth through Age 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Neonates Requiring Exchange Transfusions</measure>
    <time_frame>Post-Birth through Age 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of phototherapy required by neonate</measure>
    <time_frame>Post-Birth through Age 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Neonates Requiring Simple Transfusions in the First 3 Months of Life</measure>
    <time_frame>Post-Birth through Age 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Simple Transfusions Required by Neonate in the First 3 Months of Life</measure>
    <time_frame>Post-Birth through Age 3 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN)</condition>
  <condition>Erythroblastosis, Fetal</condition>
  <arm_group>
    <arm_group_label>Pregnant women and their offspring from current pregnancy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No investigational drugs will be administered as part of the study</description>
    <arm_group_label>Pregnant women and their offspring from current pregnancy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants must have an obstetrical history of severe fetal anemia, hydrops, or
        stillbirth related to hemolytic disease of the fetus and newborn, have alloantibody titers
        for anti-D ≥32 or anti-Kell titers ≥4, and be currently pregnant with an antigen-positive
        fetus. Eligible women may enter the study at any time during the current pregnancy prior to
        delivery.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Pregnant female participants must be ≥18 years of age with an estimated Gestational Age of
        ≥ 8 weeks; not currently pregnant with multiples (twins or more); and no other clinically
        relevant abnormalities currently or in their history that the Investigator would deem them
        ineligible to participate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Momenta General Queries</last_name>
    <role>Study Director</role>
    <affiliation>Momenta Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Momenta General Queries</last_name>
    <phone>+1 617-715-5094</phone>
    <email>ClinicalTrialInfo@momentapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Momenta Investigational Site</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemolytic disease of the fetus and newborn (HDFN)</keyword>
  <keyword>Erythroblastosis, Fetal</keyword>
  <keyword>Early onset severe hemolytic disease of the fetus and newborn (EOS-HDFN)</keyword>
  <keyword>M281</keyword>
  <keyword>Pregnant Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythroblastosis, Fetal</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

